# Beijing Riltide Medicines Co.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/beijing-riltide-medicines-co

- Industry: Pharmaceuticals
- Headquarters: Beijing, China
- Website: www.riltide.com/
- Latest round: Seed (Oct 20, 2025)
- Investors on record: 2

## About

Founded in 2024 and based in Beijing, China, Beijing Riltide Medicines Co., Ltd. is engaged in developing innovative data solutions. In October 2025, the company closed seed funding led by new investor NRL Capital, with participation from Yitan Investment. 
The company specializes in advanced technological solutions primarily focused on enhancing data analytics and operational efficiency for businesses across various sectors. Their core product offerings include a robust data management platform designed to streamline data integration, analytics, and reporting for enterprises. This platform serves clientele, including mid-sized and large enterprises in industries such as finance, healthcare, and logistics, facilitating improved decision-making and operational insights. 
The company generates revenue through a subscription-based model, offering clients access to its data management platform with various tiers based on the level of features and support required. Businesses may choose from standard, premium, or enterprise plans, each providing different capabilities tailored to their operational needs.
The company will use the seed funding to advance the pre-clinical R&D of its core pipelines and to build and improve the AI interactive molecular design platform.

## Funding rounds

- Seed, Oct 20, 2025 — NRL Capital, Yitan Investment

## Investors

- NRL Capital (https://capitalatlas.ai/funds/nrl-capital) — Seed
- Yitan Investment (https://capitalatlas.ai/funds/yitan-investment) — Seed